BiVictriX Therapeutics plc Stock OTC Markets

BVTXF

GB00BNXH3K91

Biotechnology & Medical Research

OTC Markets Traded

Latest news : BiVictriX Therapeutics plc

12/06/25	BiVictriX Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/05/25	Bivictrix Limited Announces Termination of Mrs. Susan Day Lowther as Director, Effective May 23, 2025	CI
28/05/25	BiVictriX Therapeutics plc Appoints Michael Glen Kauffman as Director, Effective May 23, 2025	CI
09/09/24	Bivictrix Therapeutics optimistic about BVX002 after in vivo testing	AN
09/09/24	BiVictriX's Ovarian Cancer Drug Conjugate Demonstrates Tumor Growth Inhibition	MT
12/08/24	Stocks rise as focus moves to economic data	AN
12/08/24	Bivictrix Therapeutics to delist as AIM offers insufficient liquidity	AN
12/08/24	AIM WINNERS & LOSERS: Global Petroleum jumps on potential Namibia deal	AN
12/08/24	BiVictriX Plans Delisting from London's AIM in September	MT
12/08/24	Bharti Global to build near 25% stake in BT	AN
01/08/24	Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Reports H1 Loss GBX-1.79	MT
01/08/24	BiVictriX Therapeutics plc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
21/06/24	BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

More news

Press Releases: BiVictriX Therapeutics plc

11/09/24	BiVictriX Therapeutics plc Shares now trading on JP Jenkins	EQ
06/10/23	BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	AQ
20/09/23	BiVictriX Therapeutics "looking really healthy" after positive first half	AQ
23/08/23	BiVictriX Therapeutics passes "exciting milestone" with US patent for BVX001	AQ
30/03/23	BiVictriX Therapeutics to "continue seeking out positive relationships"	AQ

More press releases

Managers and Directors: BiVictriX Therapeutics plc

Manager	Title	Age	Since
Tiffany Thorn CEO	Chief Executive Officer	39	01/01/2016
Adrian Howd DFI	Director of Finance/CFO	54	03/10/2023
Alison Halsall SEC	Corporate Secretary	-	13/10/2023

Director	Title	Age	Since
Tiffany Thorn BRD	Director/Board Member	39	01/01/2016
Susan Lowther BRD	Director/Board Member	67	22/09/2021
William Paris BRD	Director/Board Member	75	22/09/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIVICTRIX THERAPEUTICS PLC	-.--%	-.--%	-	-	10.49M
LONZA GROUP AG	+1.68%	+3.19%	+3.55%	+10.97%	50.44B
REVOLUTION MEDICINES, INC.	+0.72%	+1.00%	+396.18%	+624.25%	40.63B
IQVIA HOLDINGS INC.	+2.54%	+0.93%	+28.98%	-3.62%	34.88B
BEONE MEDICINES AG	+0.31%	+1.74%	+18.44%	+59.76%	33.67B
CELLTRION, INC.	-2.09%	-1.98%	+3.21%	+33.56%	26.29B
ASCENDIS PHARMA A/S	-0.63%	+0.34%	-	-	17.11B
MEDPACE HOLDINGS, INC.	+0.66%	-3.96%	+66.85%	+127.36%	15.29B
IONIS PHARMACEUTICALS, INC.	-23.90%	-21.43%	+50.06%	+53.83%	10.62B
EUROFINS SCIENTIFIC SE	+2.59%	-0.49%	+15.24%	+21.25%	13.74B
Average	-1.81%	-2.71%	+72.81%	+115.92%	26.96B
Weighted average by Cap.	-0.25%	-0.61%	+87.59%	+139.64%

See all sector performances

BiVictriX Therapeutics plc is a drug discovery and development company. The Company is focused on leveraging clinical experience to develop highly selective cancer therapeutics. The Company generates a proprietary pipeline of Bi-Cygni Antibody Drug Conjugate (ADC) therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints, on tumour cells, which are largely absent from healthy cells. The Company utilizes these novel Bi-Cygni fingerprints, together with the Companyâ€™s novel Antibody Drug Conjugate therapeutic design, to develop therapeutics to target cancers. Its pipeline includes BVX001, BVX002 and BVX003. Its lead program: BVX001 is a Bi-Cygni ADC designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with Acute Myeloid Leukaemia (AML), and in subpopulations of cancer cells from patients with other haematological cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company